

**DESCRIPTION**

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects a synthetic peptide corresponding to residues near amino acid 500 of human SLC1A5 protein by Direct ELISA.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 1085750
<b>Purification</b>	Protein A or G purified
<b>Immunogen</b>	Synthetic Peptide Accession # Q15758
<b>Conjugate</b>	Alexa Fluor Plus 555 Excitation Wavelength: 558 nm Emission Wavelength: 572 nm
<b>Formulation</b>	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<b>Western Blot</b>	Optimal dilution of this antibody should be experimentally determined.
<b>Immunocytochemistry</b>	Optimal dilution of this antibody should be experimentally determined.
<b>Immunohistochemistry</b>	Optimal dilution of this antibody should be experimentally determined.

**DATA**

**PREPARATION AND STORAGE**

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

**BACKGROUND**

SLC1A5 is a sodium dependent antiporter also known as ASCT2 (ASC amino acid Transporter2). It is a member of the solute carrier (SLC) superfamily of transporters and plays an important role in tumors. It is one of the 3 proteins, including SLC7A5 and SLC3A2, that are among the highest differentially expressed genes in activated lymphocytes and cancerous cells. Pharmacological inhibition of SLC1A5 was found to abrogate the effector functions of NK cells. In a pancancer analysis of SLC1A5, it has been demonstrated to be a prognostic biomarker in cancer patients.

**References:**

1. Nachev M, Ali AK, Almutairi SM, Lee SH. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. *Front Immunol.* 2021 Apr 19;12:624324. doi: 10.3389/fimmu.2021.624324. PMID: 33953707; PMCID: PMC8089370.
2. Chen P, Jiang Y, Liang J, Cai J, Zhuo Y, Fan H, Yuan R, Cheng S, Zhang Y. SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis. *Aging (Albany NY).* 2023 Aug 10;15(15):7451-7475. doi: 10.18632/aging.204911. Epub 2023 Aug 10. PMID: 37566748; PMCID: PMC10457057.

**PRODUCT SPECIFIC NOTICES**

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or [outlicensing@thermofisher.com](mailto:outlicensing@thermofisher.com).